Involvement of organic cation transporter-3 and plasma membrane monoamine transporter in serotonin uptake in human brain vascular smooth muscle cells

Frontiers in Pharmacology

Volumn 4 FEB, Issue , 2013, Pages

  Li, Rachel W S ^a   Yang, Cui ^a   Kwan, Y W ^b   Chan, S W ^c   Lee, Simon M Y ^d   Leung, George P H ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^d University of Macau   (Macao)

Author keywords

Monoamine transporter; Organic cation transporter; Serotonin; Vascular smooth muscle cells

Indexed keywords

1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; CARRIER PROTEIN; CITALOPRAM; DAT PROTEIN; DESIPRAMINE; DOPAMINE TRANSPORTER; MESSENGER RNA; NET PROTEIN; NORADRENALIN TRANSPORTER; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; PLASMA MEMBRANE MONOAMINE TRANSPORTER; SEROTONIN; SEROTONIN H 3; SEROTONIN TRANSPORTER; SMALL INTERFERING RNA; SODIUM ION; UNCLASSIFIED DRUG;

ARTICLE; BRAIN BLOOD VESSEL; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; IC 50; KINETICS; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROTONIN UPTAKE; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

EID: 84881492556     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00014     Document Type: Article

References (50)

1. Amenta, F., De Rossi, M., Mione, M. C., and Geppetti, P. (1985). Characterization of [3H]5-hydroxytryptamine uptake within rat cerebrovascular tree. Eur. J. Pharmacol. 112, 181-186.
2. Baganz, N. L., Horton, R. E., Calderon, A. S., Owens, W. A., Munn, J. L., Watts, L. T., et al. (2008). Organic cation transporter 3: keeping the brake on extracellular serotonin in serotonin-transporter-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 105, 18976-18981.
3. Banes, A. K., and Watts, S. W. (2003). Arterial expression of 5-HT2B and 5-HT1B receptors during development of DOCA-salt hypertension. BMC Pharmacol. 3:12. doi:10.1186/1471-2210-3-12
4. Bengel, D., Murphy, D. L., Andrews, A. M., Wichems, C. H., Feltner, D., Heils, A., et al. (1998). Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice. Mol. Pharmacol. 53, 649-655.
5. Bhattacharyya, S., Puri, S., Miledi, R., and Panicker, M. M. (2002). Internalization and recycling of 5-HT2A receptors activated by serotonin and protein kinase C-mediated mechanisms. Proc. Natl. Acad. Sci. U.S.A. 99, 14470-14475.
6. Chen, J. J., Li, Z., Pan, H., Murphy, D. L., Tamir, H., Koepsell, H., et al. (2001). Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: abnormal intestinal motility and the expression of cation transporters. J. Neurosci. 21, 6348-6361.
7. Collis, M. G., and Vanhoutte, P. M. (1981). Tachyphylaxis to 5-hydroxytryptamine in perfused kidneys from spontaneously hypertensive and normotensive rats. J. Cardiovasc. Pharmacol. 3, 229-235.
8. Daws, L. C., Toney, G. M., Gerhardt, G. A., and Frazer, A. (1998). In vivo chronoamperometric measures of extracellular serotonin clearance in rat dorsal hippocampus: contributions of serotonin and norepinephrine transporters. J. Pharmacol. Exp. Ther. 286, 967-976.
9. Dohi, Y., and Lüscher, T. F. (1991). Altered intra- and extraluminal effects of 5-hydroxytryptamine in hypertensive mesenteric resistance arteries: contribution of the endothelium and smooth muscle. J. Cardiovasc. Pharmacol. 18, 278-284.
10. Eddahibi, S., Fabre, V., Boni, C., Martres, M. P., Raffestin, B., Hamon, M., et al. (1999). Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells. Relationship with the mitogenic action of serotonin. Circ. Res. 84, 329-336.
11. Eddahibi, S., Humbert, M., Fadel, E., Raffestin, B., Darmon, M., Capron, F., et al. (2001). Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J. Clin. Invest. 108, 1141-1150.
12. Engel, K., and Wang, J. (2005). Interaction of organic cations with a newly identified plasma membrane monoamine transporter. Mol. Pharmacol. 68, 1397-1407.
13. Engel, K., Zhou, M., and Wang, J. (2004). Identification and characterization of a novel monoamine transporter in the human brain. J. Biol. Chem. 279, 50042-50049.
14. Fukuroda, T., Fujikawa, T., Ozaki, S., Ishikawa, K., Yano, M., and Nishikibe, M. (1994). Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem. Biophys. Res. Commun. 199, 1461-1465.
15. Golino, P., Piscione, F., Willerson, J. T., Cappelli-Bigazzi, M., Focaccio, A., Villari, B., et al. (1991). Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N. Engl. J. Med. 324, 641-648.
16. Gorboulev, V., Ulzheimer, J. C., Akhoundova, A., Ulzheimer-Teuber, I., Karbach, U., Quester, S., et al. (1997). Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 16, 871-881.
17. Gray, J. A., Bhatnagar, A., Gurevich, V. V., and Roth, B. L. (2003). The interaction of a constitutively active arrestin with the arrestin-insensitive 5-HT2A receptor induces agonist-independent internalization. Mol. Pharmacol. 63, 961-972.
18. Gründemann, D., Schechinger, B., Rappold, G. A., and Schömig, E. (1998). Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat. Neurosci. 1, 349-351.
19. Hayer-Zillgen, M., Brüss, M., and Bönisch, H. (2002). Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br. J. Pharmacol. 136, 829-836.
20. Hirano, K., Seki, T., Sakai, N., Kato, Y., Hashimoto, H., Uchida, S., et al. (2005). Effects of continuous administration of paroxetine on ligand binding site and expression of serotonin transporter protein in mouse brain. Brain Res. 1053, 154-161.
21. Homberg, J., Mudde, J., Braam, B., Ellenbroek, B., Cuppen, E., and Joles, J. A. (2006). Blood pressure in mutant rats lacking the 5-hydroxytryptamine transporter. Hypertension 48, E115-E116.
22. Horvath, G., Sutto, Z., Torbati, A., Conner, G. E., Salathe, M., and Wanner, A. (2003). Norepinephrine transport by the extraneuronal monoamine transporter in human bronchial arterial smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 285, L829-L837.
23. Hutri-Kähönen, N., Kähönen, M., Wu, X., Sand, J., Nordback, I., Taurio, J., et al. (1999). Control of vascular tone in isolated mesenteric arterial segments from hypertensive patients. Br. J. Pharmacol. 127, 1735-1743.
24. Jonker, J. W., and Schinkel, A. H. (2004). Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J. Pharmacol. Exp. Ther. 308, 2-9.
25. Koepsell, H., Lips, K., and Volk, C. (2007). Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm. Res. 24, 1227-1251.
26. Krygicz, D., Azzadin, A., Pawlak, R., Malyszko, J. S., Pawlak, D., Mysliwiec, M., et al. (1996). Cyclosporine A affects serotonergic mechanisms in uremic rats. Pol. J. Pharmacol. 48, 351-354.
27. Lee, S. L., Wang, W. W., Moore, B. J., and Fanburg, B. L. (1991). Dual effect of serotonin on growth of bovine pulmonary artery smooth muscle cells in culture. Circ. Res. 68, 1362-1368.
28. Linder, A. E., Diaz, J., Ni, W., Szasz, T., Burnett, R., and Watts, S. W. (2008a). Vascular reactivity, 5-HT uptake, and blood pressure in the serotonin transporter knockout rat. Am. J. Physiol. Heart Circ. Physiol. 294, H1745-H1752.
29. Linder, A. E., Ni, W., Szasz, T., Burnett, R., Diaz, J., Geddes, T. J., et al. (2008b). A serotonergic system in veins: serotonin transporter-independent uptake. J. Pharmacol. Exp. Ther. 325, 714-722.
30. Martel, F., and Azevedo, I. (2003). An update on the extraneuronal monoamine transporter (EMT): characteristics, distribution and regulation. Curr. Drug Metab. 4, 313-318.
31. Martel, F., Monteiro, R., and Lemos, C. (2003). Uptake of serotonin at the apical and basolateral membranes of human intestinal epithelial (Caco-2) cells occurs through the neuronal serotonin transporter (SERT). J. Pharmacol. Exp. Ther. 306, 355-362.
32. Mirza, N. R., Nielsen, E. O., and Troelsen, K. B. (2007). Serotonin transporter density and anxiolytic-like effects of antidepressants in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 858-866.
33. Ni, W., Lookingland, K., and Watts, S. W. (2006). Arterial 5-hydroxytryptamine transporter function is impaired in deoxycorticosterone acetate and Nomega-nitro-L-arginine but not spontaneously hypertensive rats. Hypertension 48, 134-140.
34. Ni, W., Thompson, J. M., Northcott, C. A., Lookingland, K., and Watts, S. W. (2004). The serotonin transporter is present and functional in peripheral arterial smooth muscle. J. Cardiovasc. Pharmacol. 43, 770-781.
35. Nishimura, Y. (1996). Characterization of 5-hydroxytryptamine receptors mediating contractions in basilar arteries from stroke-prone spontaneously hypertensive rats. Br. J. Pharmacol. 117, 1325-1333.
36. Parsons, A. A. (1991). 5-HT receptors in human and animal cerebrovasculature. Trends Pharmacol. Sci. 12, 310-315.
37. Ramamoorthy, S., Bauman, A. L., Moore, K. R., Han, H., Yang-Feng, T., Chang, A. S., et al. (1993). Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc. Natl. Acad. Sci. U.S.A. 90, 2542-2546.
38. Schmitt, A., Mössner, R., Gossmann, A., Fischer, I. G., Gorboulev, V., Murphy, D. L., et al. (2003). Organic cation transporter capable of transporting serotonin is up-regulated in serotonin transporter-deficient mice. J. Neurosci. Res. 71, 701-709.
39. Soares-da-Silva, P., Pestana, M., Vieira-Coelho, M. A., Fernandes, M. H., and Albino-Teixeira, A. (1995). Assessment of renal dopaminergic system activity in the nitric oxide-deprived hypertensive rat model. Br. J. Pharmacol. 114, 1403-1413.
40. Tahara, H., Kusuhara, H., Chida, M., Fuse, E., and Sugiyama, Y. (2006). Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists. J. Pharmacol. Exp. Ther. 316, 1187-1194.
41. Vanhoutte, P. M. (1990). Serotonergic antagonists and vascular disease. Cardiovasc. Drugs Ther. 4(Suppl. 1), 7-12.
42. Wanstall, J. C., Fiore, S. A., Gambino, A., and Chess-Williams, R. (2003). Potentiation of 5-hydroxytryptamine (5-HT) responses by a 5-HT uptake inhibitor in pulmonary and systemic vessels: effects of exposing rats to hypoxia. Naunyn Schmiedebergs Arch. Pharmacol. 368, 520-527.
43. Watts, S. W. (1998). The development of enhanced arterial serotonergic hyperresponsiveness in mineralocorticoid hypertension. J. Hypertens. 16, 811-822.
44. Watts, S. W. (2002). Serotonin-induced contraction in mesenteric resistance arteries: signaling and changes in deoxycorticosterone acetate-salt hypertension. Hypertension 39, 825-829.
45. Wright, S. H., and Dantzler, W. H. (2004). Molecular and cellular physiology of renal organic cation and anion transport. Physiol. Rev. 84, 987-1049.
46. Wu, X., Huang, W., Ganapathy, M. E., Wang, H., Kekuda, R., Conway, S. J., et al. (2000). Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am. J. Physiol. Renal Physiol. 279, F449-F458.
47. Wyse, D. G. (1984). Relationship of blood pressure to the responsiveness of an isolated human artery to selected agonists and to electrical stimulation. J. Cardiovasc. Pharmacol. 6, 1083-1091.
48. Zhang, L., Dresser, M. J., Gray, A. T., Yost, S. C., Terashita, S., and Giacomini, K. M. (1997). Cloning and functional expression of a human liver organic cation transporter. Mol. Pharmacol. 51, 913-921.
49. Zhang, S., Lovejoy, K. S., Shima, J. E., Lagpacan, L. L., Shu, Y., Lapuk, A., et al. (2006). Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 66, 8847-8857.
50. Zhou, F. C., Lesch, K. P., and Murphy, D. L. (2002). Serotonin uptake into dopamine neurons via dopamine transporters: a compensatory alternative. Brain Res. 942, 109-119.